Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Global Times.
Press releases published on May 2, 2025
JA Mining Integrates XRP for Enhanced Cloud Mining Services, Paving the Way for Faster, Affordable Crypto Payments
GlobeNewswire
·
May 2, 2025
JA Mining Introduces Passive Income for XRP Users WARWICK, United Kingdom, May 02, 2025 (GLOBE NEWSWIRE) -- JA Mining, a leading cloud mining platform, has announced the integration of XRP into its mining operations, positioning itself as a major player in …
xSuite Asia Invites Customers to the 2025 User Conference in Singapore
GlobeNewswire
·
May 2, 2025
Under the Theme "One Team. One Journey," the Software Provider Showcases Innovations and Solutions for the Finance Sector Singapore, May 2, 2025 – xSuite Asia invites users to join the 2025 User Conference, taking place on May 29 in Singapore, for an in- …
EXA Infrastructure selects Nokia to expand international connectivity network capabilities
GlobeNewswire
·
May 2, 2025
Press Release EXA Infrastructure selects Nokia to expand international connectivity network capabilities EXA Infrastructure’s modernized network will support data center connectivity with significantly lower cost and power per bit to keep up with demand in …
EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
GlobeNewswire
·
May 2, 2025
Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, …
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
GlobeNewswire
·
May 2, 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here. …
Shell announces commencement of a share buyback programme
GlobeNewswire
·
May 2, 2025
Shell plc Shell announces commencement of a share buyback programme May 2, 2025 Shell plc (the ‘Company’) today announces the commencement of a $3.5 billion share buyback programme covering an aggregate contract term of approximately three months (the ‘ …
Shell plc First Quarter 2025 Interim Dividend
GlobeNewswire
·
May 2, 2025
London, May 2, 2025 − The Board of Shell plc (the “Company”) (XLON: SHEL, XNYS: SHEL, XAMS: SHELL) today announced an interim dividend in respect of the first quarter of 2025 of US$ 0.358 per ordinary share. Details relating to the first quarter 2025 …
Shell plc publishes first quarter 2025 press release
GlobeNewswire
·
May 2, 2025
London, May 2, 2025 "Shell delivered another solid set of results in the first quarter of 2025. We further strengthened our leading LNG business by completing the acquisition of Pavilion Energy, and high-graded our portfolio with the completion of the …
301,521 Orion Corporation A shares converted into B shares
GlobeNewswire
·
May 2, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles …
Shell Plc 1st Quarter 2025 Unaudited Results
GlobeNewswire
·
May 2, 2025
SHELL PLC 1st QUARTER 2025 UNAUDITED RESULTS SUMMARY OF UNAUDITED RESULTS Quarters $ million Q1 2025 Q4 2024 Q1 2024 %¹ Reference 4,780 928 7,358 +415 …
301 521 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
GlobeNewswire
·
May 2, 2025
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 2.5.2025 KLO 9.00 301 521 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 301 521 …
Aalberts N.V.: Aalberts reports first quarter 2025 results
GlobeNewswire
·
May 2, 2025
Utrecht, 2 May 2025 Aalberts reports first quarter 2025 results In the first quarter Aalberts realised EUR 778.3 million revenue, which translates into 3.3% organic revenue decline compared to the first quarter of last year. We realised EUR 105.7 million …
ING completes share buyback and announces new programme of up to €2.0 billion
GlobeNewswire
·
May 2, 2025
ING completes share buyback and announces new programme of up to €2.0 billion ING announced today that it has completed the share buyback programme announced on 31 October 2024. The total number of ordinary shares repurchased under the programme is 125,848 …
ING posts 1Q2025 net result of €1,455 million, with strong growth in customer balances and fee income
GlobeNewswire
·
May 2, 2025
CEO statement “While the geopolitical and macroeconomic circumstances remain uncertain, we believe there is an opportunity for Europe to collectively drive competitiveness and resilience through simplification of regulations and investments in …
Equinor sells the Peregrino field for USD 3.5 billion
GlobeNewswire
·
May 2, 2025
Equinor Brasil Energia Ltda., a subsidiary of Equinor (OSE: EQNR, NYSE: EQNR), has entered into agreements(1) with Brazilian company Prio Tigris Ltda., a subsidiary of PRIO SA (PRIO3.SA) for a sale of its 60% operated interest in the Peregrino field in …
Equinor selger Peregrino-feltet for 3,5 milliarder USD
GlobeNewswire
·
May 2, 2025
Equinor Brasil Energia Ltda., et datterselskap av Equinor ASA (OSE:EQNR, NYSE: EQNR), har inngått avtaler(1) om salg av sin egenopererte eierandel på 60 prosent i Peregrino-feltet i Brasil med det brasilianske selskapet Prio Tigris Ltda. (PRIO3.SA). PRIO, …
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
GlobeNewswire
·
May 2, 2025
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming …